ArticleInternational urology and nephrology2026
Construction of a nomogram model for clinically significant prostate cancer based on biparametric magnetic resonance imaging.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Promising but preliminary: a critical appraisal of the validation and generalizability of penKid for SA-AKI prediction.International urology and nephrology · 2026Article
- Critical perspectives on proenkephalin A 119-159 for shock-associated acute kidney injury.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo evaluate and compare the diagnostic performance of clinical features and PI-RADS v2.1 for identifying clinically significant prostate cancer (csPCa) and to assess whether a combined model improves detection.
methodsThis retrospective study analyzed patients who underwent biparametric MRI (bpMRI). csPCa was defined as ISUP grade ≥ 2 with pathological T-stage ≥ pT2a (prostatectomy) or PI-RADS score ≥ 4 (biopsy). PI-RADS v2.1 scores were assigned independently. PSAD was calculated as tPSA/prostate volume. Univariate and multivariable logistic regression identified predictors, with performance assessed by ROC analysis. Subgroup analyses were conducted for tPSA 4-10 ng/mL and 10-20 ng/mL.
resultsOf 192 patients, 73 were classified as csPCa. Multivariable analysis confirmed PSAD (OR = 1.80, P = 0.008) and PI-RADS (OR = 4.50, p < 0.001) as independent predictors. The combined PSAD + PI-RADS model achieved an AUC of 0.830 (95% CI 0.801-0.869), with 83.6% sensitivity and 78.2% specificity. Subgroup analyses showed consistent high performance in both the 4-10 ng/mL (AUC = 0.805) and 10-20 ng/mL (AUC = 0.855) PSA ranges.
conclusionPSAD and PI-RADS v2.1 are independent predictors of csPCa under a composite definition. Their combination provides superior diagnostic accuracy, offering an effective strategy for risk stratification and biopsy decision-making in patients with tPSA 4-20 ng/mL.
Indexed as
Identifiers
41410894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.